Additional Subscription for 11m Shares

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that, further to the Company's announcements dated 22 September 2025 regarding the Placing and Subscription which raised gross proceeds of £5.20 million, the Company has entered into an additional subscription agreement following inbound interest from a new institutional investor (the "Additional Subscription").

Pursuant to the terms of the Additional Subscription Agreement, ABRDN World Healthcare Fund has subscribed for 11,000,000 Subscription Shares at the Issue Price of 9.5 pence per share (the "Additional Subscription Shares") for an aggregate Subscription of £1.045 million ($1.410 million).

The funds raised via the Additional Subscription will further support the Company's commercial distribution efforts, which includes the recently announced collaboration with Tempus AI, Inc. (NASDAQ: TEM).

James McCullough, CEO of Renalytix, commented: "We are particularly pleased with the strong institutional support we have received at this critical time for accelerating growth with our U.S. kidneyintelX.dkd prognostic testing and unique data accumulation program in diabetes and kidney disease."

Admission and Total Voting Rights

Application will be made to the London Stock Exchange for the Additional Subscription Shares to be admitted to trading on the AIM. It is expected that Admission of the Additional Subscription Shares will become effective and that dealings in the Additional Subscription Shares will commence at 8.00 a.m. on Monday 29 September 2025, the same day as the 45,487,903 Second Tranche Placing Shares. This will follow the Admission of the 9,253,679 First Tranche Placing Shares on Friday 26 September 2025. The Retail Offer Shares are also expected to be admitted to trading on AIM on Monday 29 September 2025.

The Additional Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

A further announcement will be made regarding the Company's enlarged issued share capital and Total Voting Rights once the result of the Retail Offer has been confirmed.

Capitalised terms used in this announcement have the meanings given to them in the Company's 'Proposed Fundraise' and 'Result of Fundraise' announcements dated 22 September 2025, unless the context provides otherwise.

James McCullogh, Chief Executive Officer.